Hologic (HOLX)

• Market cap: $13.8B
• 1 day: -0.65%
• 5 days: -2.88%
• 1 month: -4.59%
• 3 months: -17.58%
• 6 months: -25.20%
• Year to date: -15.39%
• 1 year: -20.48%
• 5 years: 49.58%
• 10 years: 87.98%
• Sector: Healthcare
• Industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $39.4M | Put options by funds: $36.2M

2% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 85

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0.33% less ownership

Funds ownership: 97.79% [Q3] → 97.45% (-0.33%) [Q4]

2% less funds holding

Funds holding: 712 [Q3] → 700 (-12) [Q4]

12% less capital invested

Capital invested by funds: $18.5B [Q3] → $16.3B (-$2.19B) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 248 | Existing positions reduced: 284

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 15% upside
• Avg. target: $80 32% upside
• High target: $90 48% upside

7 analyst ratings

• positive: 2 29%
• neutral: 5 71%
• negative: 0 0%

Citigroup Patrick Donnelly 23% 1-year accuracy 7 / 31 met price target	15% upside $70	Neutral Maintained	4 Mar 2025
Raymond James Andrew Cooper 7% 1-year accuracy 1 / 15 met price target	48% upside $90	Outperform Reiterated	6 Feb 2025
RBC Capital Conor McNamara 3% 1-year accuracy 1 / 36 met price target	40% upside $85	Sector Perform Maintained	6 Feb 2025
Evercore ISI Group Vijay Kumar 40% 1-year accuracy 19 / 47 met price target	20% upside $73	In-Line Maintained	6 Feb 2025
Stephens & Co. Mason Carrico 21% 1-year accuracy 5 / 24 met price target	38% upside $84	Overweight Reiterated	6 Feb 2025